ArticleJournal of inflammation research2025
Development and Validation of a New Immune-Inflammatory-Nutritional Score to Predict Pathological Complete Response in Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy: A Two-Center Study.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of prognostic nutritional index in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Predicting the prognosis of breast cancer patients by using nutrition-based index: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- PIV, PNI and HALP score for predicting pathological complete response in breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Development and verification of a prognostic nomogram model for triple-negative breast cancer patients with neoadjuvant therapy.Frontiers in oncology · 2026Article
- The role of AI-driven decision support in immunotherapy for predicting pathological complete response in triple-negative breast cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To construct a novel immune-inflammatory-nutritional (IIN) score based on peripheral blood biomarkers related to inflammation, immunity, and nutrition, and to predict the efficacy of neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC). Patients and Methods: We retrospectively selected 431 patients with TNBC from Xijing Hospital, and then randomly divided the patients into a training set and an internal validation set in a ratio of 7:3. An external validation set was included with 154 patients selected from West China Hospital of Sichuan University. In the training set, patients were divided into the pathological complete response (pCR) group and the non-pathological complete response group. Univariate logistic regression analysis and LASSO regression analysis were used to select biomarkers that affect the efficacy of NAC in TNBC patients and to construct the IIN score. A nomogram model was constructed based on the IIN score and clinical pathological characteristics to predict whether TNBC patients could achieve pCR after NAC before treatment. The predictive performance and clinical application value of the nomogram model were assessed using the receiver operating characteristic (ROC) curve, calibration curve, decision curve analysis, and confusion matrix. Results: Through LASSO regression analysis, 6 biomarkers were ultimately identified to construct the scoring system. A nomogram model was constructed based on the IIN score and clinical pathological characteristics, and the ROC curve showed the areas under the curve to be 0.827, 0.786, and 0.754 in the training set, internal validation set, and external validation set, respectively. Calibration curves, decision curves, and confusion matrices all demonstrated that the nomogram model exhibited robust predictive performance and holds certain clinical application value. Conclusion: The nomogram model based on the IIN score offers high predictive performance and can accurately predict the efficacy of NAC in TNBC patients before treatment, highlighting its clinical application potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.